Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jason Madore

Showing results (31-40 of 47) with videos related to

Pageof 5
Sort By:
Cancer Research|June 28, 2017
MAPK Signaling and Inflammation Link Melanoma Phenotype Switching to Induction of CD73 during ImmunotherapyJulia Reinhardt, Jennifer Landsberg, Jonathan L Schmid-Burgk, et al.
Histopathology|November 21, 2015
Programmed death ligand 1 expression in triple-negative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcomeRhiannon K Beckers, Christina I Selinger, Ricardo Vilain, et al.
Scientific Reports|March 10, 2019
Author Correction: RGS7 is recurrently mutated in melanoma and promotes migration and invasion of human cancer cellsNouar Qutob, Ikuo Masuho, Michal Alon, et al.
Scientific Reports|January 14, 2018
RGS7 is recurrently mutated in melanoma and promotes migration and invasion of human cancer cellsNouar Qutob, Ikuo Masuho, Michal Alon, et al.
Plos Genetics|November 30, 2011
Role of Pirh2 in mediating the regulation of p53 and c-MycAnne Hakem, Miyuki Bohgaki, Bénédicte Lemmers, et al.
Oncoimmunology|February 5, 2019
Integrated molecular and immunophenotypic analysis of NK cells in anti-PD-1 treated metastatic melanoma patientsHansol Lee, Camelia Quek, Ines Silva, et al.
Nature Communications|March 28, 2015
ID4 controls mammary stem cells and marks breast cancers with a stem cell-like phenotypeSimon Junankar, Laura A Baker, Daniel L Roden, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 30, 2020
Tumor CD155 Expression Is Associated with Resistance to Anti-PD1 Immunotherapy in Metastatic MelanomaAilin Lepletier, Jason Madore, Jake S O'Donnell, et al.
Cancer Cell|February 13, 2019
Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined TherapyTuba N Gide, Camelia Quek, Alexander M Menzies, et al.
Nature Genetics|October 27, 2015
Recurrent inactivating RASA2 mutations in melanomaRand Arafeh, Nouar Qutob, Rafi Emmanuel, et al.
Pageof 5

Showing results (31-40 of 47) with videos related to

Sort By:
Pageof 5
Cancer Research|June 28, 2017
MAPK Signaling and Inflammation Link Melanoma Phenotype Switching to Induction of CD73 during ImmunotherapyJulia Reinhardt, Jennifer Landsberg, Jonathan L Schmid-Burgk, et al.
Histopathology|November 21, 2015
Programmed death ligand 1 expression in triple-negative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcomeRhiannon K Beckers, Christina I Selinger, Ricardo Vilain, et al.
Scientific Reports|March 10, 2019
Author Correction: RGS7 is recurrently mutated in melanoma and promotes migration and invasion of human cancer cellsNouar Qutob, Ikuo Masuho, Michal Alon, et al.
Scientific Reports|January 14, 2018
RGS7 is recurrently mutated in melanoma and promotes migration and invasion of human cancer cellsNouar Qutob, Ikuo Masuho, Michal Alon, et al.
Plos Genetics|November 30, 2011
Role of Pirh2 in mediating the regulation of p53 and c-MycAnne Hakem, Miyuki Bohgaki, Bénédicte Lemmers, et al.
Oncoimmunology|February 5, 2019
Integrated molecular and immunophenotypic analysis of NK cells in anti-PD-1 treated metastatic melanoma patientsHansol Lee, Camelia Quek, Ines Silva, et al.
Nature Communications|March 28, 2015
ID4 controls mammary stem cells and marks breast cancers with a stem cell-like phenotypeSimon Junankar, Laura A Baker, Daniel L Roden, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 30, 2020
Tumor CD155 Expression Is Associated with Resistance to Anti-PD1 Immunotherapy in Metastatic MelanomaAilin Lepletier, Jason Madore, Jake S O'Donnell, et al.
Cancer Cell|February 13, 2019
Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined TherapyTuba N Gide, Camelia Quek, Alexander M Menzies, et al.
Nature Genetics|October 27, 2015
Recurrent inactivating RASA2 mutations in melanomaRand Arafeh, Nouar Qutob, Rafi Emmanuel, et al.
Pageof 5